Serial Fibroblast Growth Factor 23 Measurements and Risk of Requirement for Kidney Replacement Therapy: The CRIC (Chronic Renal Insufficiency Cohort) Study

被引:15
作者
Mehta, Rupal [1 ,2 ,3 ]
Cai, Xuan [2 ]
Lee, Jungwha [2 ]
Xie, Dawei [4 ,5 ]
Wang, Xue [4 ,5 ]
Scialla, Julia [7 ,8 ,19 ]
Anderson, Amanda H. [9 ]
Taliercio, Jon [10 ]
Dobre, Mirela [11 ]
Chen, Jing [9 ]
Fischer, Michael [3 ,12 ,13 ]
Leonard, Mary [14 ,15 ]
Lash, James [12 ,13 ]
Hsu, Chi-yuan [16 ]
de Boer, Ian H. [17 ,18 ]
Feldman, Harold, I [4 ,5 ,6 ]
Wolf, Myles [7 ,8 ]
Isakova, Tamara [1 ,2 ]
机构
[1] Northwestern Univ, Feinberg Sch Med, Div Nephrol & Hypertens, Dept Med, Evanston, IL 60208 USA
[2] Northwestern Univ, Feinberg Sch Med, Ctr Translat Metab & Hlth, Inst Publ Hlth & Med, Evanston, IL 60208 USA
[3] Jesse Brown Vet Adm Med Ctr, Chicago, IL USA
[4] Univ Penn, Perelman Sch Med, Dept Biostat Epidemiol & Informat, Philadelphia, PA 19104 USA
[5] Univ Penn, Perelman Sch Med, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA
[6] Univ Penn, Perelman Sch Med, Renal Electrolyte & Hypertens Div, Dept Med, Philadelphia, PA 19104 USA
[7] Duke Univ, Sch Med, Dept Med, Div Nephrol, Durham, NC 27706 USA
[8] Duke Univ, Sch Med, Duke Clin Res Inst, Durham, NC USA
[9] Tulane Univ, Sch Med, Dept Med, New Orleans, LA 70112 USA
[10] Cleveland Clin, Dept Nephrol & Hypertens, Cleveland, OH 44106 USA
[11] Cleveland Med Ctr, Univ Hosp, Div Nephrol & Hypertens, Cleveland, OH 44106 USA
[12] Univ Illinois, Coll Med, Dept Med, Div Nephrol, Chicago, IL USA
[13] Ctr Innovat Complex Chron Healthcare, Chicago, IL USA
[14] Stanford Univ, Dept Pediat, Stanford, CA 94305 USA
[15] Stanford Univ, Dept Med, Stanford, CA 94305 USA
[16] Univ Calif San Francisco, Dept Med, Div Nephrol, San Francisco, CA 94143 USA
[17] Univ Washington, Div Nephrol, Seattle, WA 98195 USA
[18] Univ Washington, Kidney Res Inst, Seattle, WA 98195 USA
[19] Univ Virginia Hlth Syst, Dept Med, Div Nephrol, Charlottesville, VA USA
基金
美国国家卫生研究院;
关键词
MARGINAL STRUCTURAL MODELS; BLOOD-PRESSURE; VITAMIN-D; PROGRESSION; DISEASE; MORTALITY; DESIGNS; CKD; TRAJECTORIES; METABOLISM;
D O I
10.1053/j.ajkd.2019.09.009
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Rationale & Objective: Studies using a single measurement of fibroblast growth factor 23 (FGF-23) suggest that elevated FGF-23 levels are associated with increased risk for requirement for kidney replacement therapy (KRT) in patients with chronic kidney disease. However, the data do not account for changes in FGF-23 levels as kidney disease progresses. Study Design: Case-cohort study. Setting & Participants: To evaluate the association between serial FGF-23 levels and risk for requiring KRT, our primary analysis included 1,597 individuals in the Chronic Renal Insufficiency Cohort Study who had up to 5 annual measurements of carboxy-terminal FGF-23. There were 1,135 randomly selected individuals, of whom 266 initiated KRT, and 462 individuals who initiated KRToutside the random subcohort. Exposure: Serial FGF-23 measurements and FGF-23 trajectory group membership. Outcomes: Incident KRT. Analytical Approach: To handle time-dependent confounding, our primary analysis of timeupdated FGF-23 levels used time-varying inverse probability weighting in a discrete time failure model. To compare our results with prior data, we used baseline and time-updated FGF-23 values in weighted Cox regression models. To examine the association of FGF-23 trajectory subgroups with risk for incident KRT, we used weighted Cox models with FGF-23 trajectory groups derived from group-based trajectory modeling as the exposure. Results: In our primary analysis, the HR for the KRT outcome per 1 SD increase in the mean of natural log-transformed (ln)FGF-23 in the past was 1.94 (95% CI, 1.51-2.49). In weighted Cox models using baseline and time-updated values, elevated FGF-23 level was associated with increased risk for incident KRT (HRs per 1 SD ln[FGF-23] of 1.18 [95% CI, 1.02-1.37] for baseline and 1.66 [95% CI, 1.49-1.86] for time-updated). Membership in the slowly and rapidly increasing FGF-23 trajectory groups was associated with similar to 3 and similar to 21-fold higher risk for incident KRT compared to membership in the stable FGF-23 trajectory group. Limitations: Residual confounding and lack of intact FGF-23 values. Conclusions: Increasing FGF-23 levels are independently associated with increased risk for incident KRT.
引用
收藏
页码:908 / 918
页数:11
相关论文
共 46 条
[1]  
Allison P. D., 1982, Sociological Methodology, V13, P61, DOI DOI 10.2307/270718
[2]   Time-Updated Systolic Blood Pressure and the Progression of Chronic Kidney Disease A Cohort Study [J].
Anderson, Amanda H. ;
Yang, Wei ;
Townsend, Raymond R. ;
Pan, Qiang ;
Chertow, Glenn M. ;
Kusek, John W. ;
Charleston, Jeanne ;
He, Jiang ;
Kallem, RadhaKrishna ;
Lash, James P. ;
Miller, Edgar R., III ;
Rahman, Mahboob ;
Steigerwalt, Susan ;
Weir, Matthew ;
Wright, Jackson T., Jr. ;
Feldman, Harold I. .
ANNALS OF INTERNAL MEDICINE, 2015, 162 (04) :258-+
[3]   Lower estimated glomerular filtration rate and higher albuminuria are associated with mortality and end-stage renal disease. A collaborative meta-analysis of kidney disease population cohorts [J].
Astor, Brad C. ;
Matsushita, Kunihiro ;
Gansevoort, Ron T. ;
van der Velde, Marije ;
Woodward, Mark ;
Levey, Andrew S. ;
de Jong, Paul E. ;
Coresh, Josef .
KIDNEY INTERNATIONAL, 2011, 79 (12) :1331-1340
[4]   Analysis of case-cohort designs [J].
Barlow, WE ;
Ichikawa, L ;
Rosner, D ;
Izumi, S .
JOURNAL OF CLINICAL EPIDEMIOLOGY, 1999, 52 (12) :1165-1172
[5]   Time-averaged level of fibroblast growth factor-23 and clinical events in chronic kidney disease [J].
Bouma-de Krijger, Annet ;
Bots, Michiel L. ;
Vervloet, Marc G. ;
Blankestijn, Peter J. ;
ter Wee, Pieter W. ;
van Zuilen, Arjan D. ;
Wetzels, Jack F. .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2014, 29 (01) :88-97
[6]   Bicarbonate Supplementation Slows Progression of CKD and Improves Nutritional Status [J].
de Brito-Ashurst, Ione ;
Varagunam, Mira ;
Raftery, Martin J. ;
Yaqoob, Muhammad M. .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2009, 20 (09) :2075-2084
[7]   Fibroblast Growth Factor 23: A Biomarker of Kidney Function Decline [J].
Drew, David A. ;
Katz, Ronit ;
Kritchevsky, Stephen ;
Ix, Joachim H. ;
Shlipak, Michael G. ;
Newman, Anne B. ;
Hoofnagle, Andy ;
Fried, Linda ;
Sarnak, Mark J. ;
Gutierrez, Orlando M. .
AMERICAN JOURNAL OF NEPHROLOGY, 2018, 47 (04) :242-250
[8]   The Chronic Renal Insufficiency Cohort (CRIC) study: Design and methods [J].
Feldman, HI ;
Appel, LJ ;
Chertow, GM ;
Cifelli, D ;
Cizman, B ;
Daugirdas, J ;
Fink, JC ;
Franklin-Becker, ED ;
Go, AS ;
Hamm, LL ;
He, JA ;
Hostetter, T ;
Hsu, CY ;
Jamerson, K ;
Joffe, M ;
Kusek, JW ;
Landis, JR ;
Lash, JP ;
Miller, ER ;
Mohler, ER ;
Muntner, P ;
Ojo, AO ;
Rahman, M ;
Townsend, RR ;
Wright, JT .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2003, 14 (07) :S148-S153
[9]   Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: The mild to moderate kidney disease (MMKD) study [J].
Fliser, Danilo ;
Kollerits, Barbara ;
Neyer, Ulrich ;
Ankerst, Donna P. ;
Lhotta, Karl ;
Lingenhel, Arno ;
Ritz, Eberhard ;
Kronenberg, Florian .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2007, 18 (09) :2600-2608
[10]   Mechanisms of progression of chronic kidney disease [J].
Fogo, Agnes B. .
PEDIATRIC NEPHROLOGY, 2007, 22 (12) :2011-2022